Loading...
Loading...
Monopar Therapeutics
Monopar Therapeutics. Spoken Alpha tracks MNPR's earnings calls, guidance changes, and executive accountability over time.
Spoken Alpha tracks MNPR's historical accountability: how often management beat consensus, how the stock reacted, and how guidance evolved across the cycle. The figures below are illustrative placeholder data generated for layout — they will be replaced with real deviation metrics, True Consensus values, and EODHD price reactions as those data layers land.
Beats consensus 10/10 quarters with 60% positive reaction rate
SampleConsistent execution against consensus with the stock following through is the cleanest signal a guidance regime is calibrated. Worth watching for the inflection where execution deteriorates relative to the bar.
Raised guidance 8 quarters in a row
SampleConsecutive raises tighten the bar quarter over quarter. Watch the most recent print for the magnitude of the beat — a smaller beat against a higher bar is the early signal that the regime is breaking.
| Quarter | Actual EPS | Consensus | Surprise | 1D | 5D |
|---|---|---|---|---|---|
| Q1 FY2026 | $2.55 | $1.82 | +39.9% | +7.5% | +9.9% |
| Q4 FY2026 | $2.56 | $1.70 | +50.8% | +4.2% | +5.5% |
| Q3 FY2026 | $2.78 | $1.94 | +43.4% | -2.9% | -1.7% |
| Q2 FY2026 | $2.72 | $1.87 | +45.4% | +7.6% | +5.7% |
| Q1 FY2025 | $2.57 | $1.89 | +35.8% | -2.9% | -4.7% |
| Q4 FY2025 | $2.75 | $1.96 | +40.1% | +0.1% | -2.7% |
| Q3 FY2025 | $2.82 | $2.02 | +39.5% | +5.5% | +5.0% |
| Q2 FY2025 | $2.72 | $1.96 | +39.0% | +8.7% | +6.4% |
| Q1 FY2024 | $2.71 | $1.94 | +39.5% | -1.8% | -1.8% |
| Q4 FY2024 | $2.58 | $1.89 | +36.3% | -3.0% | -0.7% |
Spoken Alpha builds an accountability record per executive — how the person's own guidance, language, and reactions have evolved across every call they've appeared on. The one-liners below are illustrative placeholder data pending the deviation v1 work. Click any name for the full role timeline and call appearance history.
CEO since 2025 • 1/4 beats (25%) • last guidance raise Q3 FY2026
CFO since 2025 • 3/4 beats (75%) • guidance suspended Q3 FY2026
COO since 2025 • 2/4 beats (50%) • last guidance raise Q2 FY2026
OTHER since 2026 • 1/2 beats (50%) • last guidance cut Q3 FY2026
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for MNPR.
curl https://api.spokenalpha.com/v1/companies/MNPR